Enoxaparin combined with epitfibatide or abciximab versus unfractionated heparin combined with epitfibatide or abciximab in percutaneous coronary intervention: obersvations on efficacy, safety, anticoagulation profile, and level of platelet inhibition
Dr Chen, Wai Hong (Principal investigator)
Professor Lau Chu Pak (Co-Investigator)
Other Funding Scheme
To compare the safety, efficacy, anticoagulation profile and level of platelet inhibition in patients undergoing percutaneous coronary intervention using enoxaparin/eptifibatide, unfractionated heparin/epitfibatide, enoxaparin/abciximab, and unfractionated heparin/abciximab.